Dosage regimes for the administration of glucagon-like-peptide-2 (GLP-2) analogues and their medical use are disclosed, for example in the treatment and/or prevention of stomach and bowel-related disorders and for ameliorating side effects of chemotherapy and radiation therapy. Dosage regimes for the administration of glucagon-like-peptide-2 (GLP- 2) analogues for inducing longitudinal growth of the intesines are described, for example for the treatment of patients with short bowel syndrome (SBS). Medical uses for adjusting the volume of parenteral support (PS) provided to subjects receiving treatment with GLP-2 analogues in response to the treatment and to algorithms for determining PS volume changes are also described.